ArticlemAbs
Prophylactic and therapeutic testing of Nicotiana-derived RSV-neutralizing human monoclonal antibodies in the cotton rat model.
Article in mAbs. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 33 citations in OpenAlex.
- Plant-Based Systems for Producing Therapeutic Proteins: Current Status and Future Prospects.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2026Review
- Neutralizing activity of anti-respiratory syncytial virus monoclonal antibody produced inHuman vaccines & immunotherapeutics · 2024Article
- Biotechnologically Engineered Plants.Biology · 2023Review
- Development of plant-made monoclonal antibodies against viral infections.Current opinion in virology · 2022Review
- Production and characterization of a human antisperm monoclonal antibody against CD52g for topical contraception in women.EBioMedicine · 2021Article
- Therapy for Argentine hemorrhagic fever in nonhuman primates with a humanized monoclonal antibody.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- Engineering monoclonal antibody-based contraception and multipurpose prevention technologies†.Biology of reproduction · 2020Review
- Plant Molecular Farming: A Viable Platform for Recombinant Biopharmaceutical Production.Plants (Basel, Switzerland) · 2020Review
- The human viral challenge model: accelerating the evaluation of respiratory antivirals, vaccines and novel diagnostics.Respiratory research · 2018Review
- Therapeutic treatment of Marburg and Ravn virus infection in nonhuman primates with a human monoclonal antibody.Science translational medicine · 2017Article
- Monoclonal antibody therapy for Junin virus infection.Proceedings of the National Academy of Sciences of the United States of America · 2016Article
- Article
- Acute and Chronic Airway Disease After Human Respiratory Syncytial Virus Infection in Cotton Rats (Sigmodon hispidus).Comparative medicine · 2015Article
- HRA2pl peptide: a fusion inhibitor for human metapneumovirus produced in tobacco plants by transient transformation.Planta · 2015Article
- Production of monoclonal antibodies in plants for cancer immunotherapy.BioMed research international · 2015Review
- Plant-based solutions for veterinary immunotherapeutics and prophylactics.Veterinary research · 2014Review
- Prevention and treatment of Clostridium perfringens epsilon toxin intoxication in mice with a neutralizing monoclonal antibody (c4D7) produced in Nicotiana benthamiana.Toxicon : official journal of the International Society on Toxinology · 2014Article
- Rapid replacement of human respiratory syncytial virus A with the ON1 genotype having 72 nucleotide duplication in G gene.Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases · 2014Article
- Glycan variants of a respiratory syncytial virus antibody with enhanced effector function and in vivo efficacy.Proceedings of the National Academy of Sciences of the United States of America · 2014Article
- Plant glyco-biotechnology on the way to synthetic biology.Frontiers in plant science · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 6 institutions in 1 country.
Funding
Abstract
Severe lower respiratory tract infection in infants and small children is commonly caused by respiratory syncytial virus (RSV). Palivizumab (Synagis(®)), a humanized IgG1 monoclonal antibody (mAb) approved for RSV immunoprophylaxis in at-risk neonates, is highly effective, but pharmacoeconomic analyses suggest its use may not be cost-effective. Previously described potent RSV neutralizers (human Fab R19 and F2-5; human IgG RF-1 and RF-2) were produced in IgG format in a rapid and inexpensive Nicotiana-based manufacturing system for comparison with palivizumab. Both plant-derived (palivizumab-N) and commercial palivizumab, which is produced in a mouse myeloma cell line, showed protection in prophylactic (p < 0.001 for both mAbs) and therapeutic protocols (p < 0.001 and p < 0.05 respectively). The additional plant-derived human mAbs directed against alternative epitopes displayed neutralizing activity, but conferred less protection in vivo than palivizumab-N or palivizumab. Palivizumab remains one of the most efficacious RSV mAbs described to date. Production in plants may reduce manufacturing costs and improve the pharmacoeconomics of RSV immunoprophylaxis and therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.